Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland 1142, New Zealand.
Bioorg Med Chem. 2013 Jun 1;21(11):3147-53. doi: 10.1016/j.bmc.2013.03.033. Epub 2013 Apr 6.
A series of 4-anilinoquinoline derivatives related to the known inhibitor SGI-1027, containing side chains of varying pK(a), were prepared by acid-catalysed coupling of the pre-formed side chains with 4-chloroquinolines. The compounds were evaluated for their ability to reduce the level of DNMT1 protein in HCT116 human colon carcinoma cells by Western blotting. With a very strongly basic N-methylpyridinium side chain, only NHCO-linked compounds were effective, whereas less strongly basic ((diaminomethylene)hydrazono)ethyl or 3-methylpyrimidine-2,4-diamine side chains allowed both NHCO- and CONH-linked compounds to show activity. In contrast, the pK(a) of the quinoline unit had little apparent influence on activity.
一系列与已知抑制剂 SGI-1027 相关的 4-苯胺喹啉衍生物,含有不同 pKa 的侧链,通过预形成的侧链与 4-氯喹啉的酸催化偶联制备而成。通过 Western 印迹法评估这些化合物降低 HCT116 人结肠癌细胞中 DNMT1 蛋白水平的能力。带有非常强碱性 N-甲基吡啶鎓侧链的情况下,只有 NHCO 连接的化合物有效,而碱性较弱的(二亚氨基甲叉)亚肼基乙基或 3-甲基嘧啶-2,4-二胺侧链允许 NHCO-和 CONH 连接的化合物都表现出活性。相比之下,喹啉单元的 pKa 对活性的影响很小。